Literature DB >> 16327838

Therapy Insight: pyoderma gangrenosum-old disease, new management.

Simon Campbell1, Sarah Cripps, Derek P Jewell.   

Abstract

Well-designed studies that help guide physicians to apply the optimal therapeutic strategy for the management of pyoderma gangrenosum are lacking in the literature. A multidisciplinary approach is paramount for the effective management of this condition, with close involvement of a wound-care specialist and a microbiologist. Treatment should be stepwise in nature. Local wound care, avoidance of trauma and the application of local steroid or tacrolimus ointment are the first-line treatments. Steroid therapy is the most widely published effective therapy for achieving resolution of pyoderma gangrenosum, although there is growing evidence for the efficacy of infliximab in refractory cases. Other therapies such as dapsone and clofazamine should be left as third-line agents for refractory pyoderma gangrenosum, while novel treatments such as granulocyte apheresis should only be used under trial conditions, to gain an objective evaluation of their efficacy. This article reviews the published treatment strategies in current use, and aims to guide the effective management of pyoderma gangrenosum.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16327838     DOI: 10.1038/ncpgasthep0339

Source DB:  PubMed          Journal:  Nat Clin Pract Gastroenterol Hepatol        ISSN: 1743-4378


  3 in total

1.  Diagnosis and management of parastomal pyoderma gangrenosum.

Authors:  Xian-Rui Wu; Bo Shen
Journal:  Gastroenterol Rep (Oxf)       Date:  2013-04-19

2.  Leukocytoclastic vasculitis in an adolescent with ulcerative colitis: Report of a case and review of the literature.

Authors:  G Tyler Butts; Phyllis R Bishop; Julie P Wyatt; Michael J Nowicki
Journal:  SAGE Open Med Case Rep       Date:  2014-08-20

3.  Extraintestinal Manifestations of Inflammatory Bowel Disease in Middle Eastern Patients.

Authors:  Heba Adam; Maryam Alqassas; Omar I Saadah; Mahmoud Mosli
Journal:  J Epidemiol Glob Health       Date:  2020-04-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.